Core Viewpoint - Globus Medical has agreed to acquire Nevro Corp in an all-cash transaction valued at approximately $250 million, with a share price of $5.85 per share, representing significant premiums over various price averages [1][2]. Company Summary - The acquisition is unanimously approved by both companies' boards and is expected to close in late Q2 2025, pending shareholder and regulatory approvals [2]. - Following the announcement, shares of Globus Medical have decreased by 0.6%, closing at $87.38, although the company is gaining market share in musculoskeletal solutions [3]. - Globus Medical has a market capitalization of $11.93 billion, with projected revenues for 2024 expected to surge by 59.4% year over year [4]. - The acquisition aligns with Globus Medical's strategy to become a leading musculoskeletal technology company, enhancing its offerings in chronic pain treatment through Nevro's HFX spinal cord stimulation platform [5][6]. Financial Projections - Upon completion of the acquisition, Globus Medical anticipates net sales of $2.80 billion to $2.90 billion and non-GAAP earnings per share between $3.10 and $3.40 for 2025 [7]. - The company has reaffirmed its standalone net sales outlook for 2025 at $2.66 billion to $2.69 billion, with non-GAAP EPS projected between $3.40 and $3.50 [7]. Industry Prospects - The global orthopedic devices market was valued at $59.4 billion in 2023, with a projected compound annual growth rate of 5.3% through 2032, driven by factors such as the rising prevalence of musculoskeletal diseases and an aging population [10]. - The recent commercial launch of the ExcelsiusHub navigation system by Globus Medical is expected to enhance surgical capabilities and reduce reliance on X-ray imaging during spine surgeries [11]. Stock Performance - Over the past year, shares of Globus Medical have increased by 67%, significantly outperforming the industry average rise of 7.7% [12].

Mergers and Acquisitions Overview - Nevro Corp. has entered into a definitive agreement with Globus Medical for $5.85 per share, with both boards unanimously approving the deal, expected to close in late Q2 2025 pending shareholder and regulatory approval [1] - ACELYRIN, INC. will be acquired by Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock, resulting in Alumis stockholders owning approximately 55% and Acelyrin stockholders 45% of the combined company on a fully diluted basis [2] - Triumph Group, Inc. has agreed to a definitive agreement with Warburg Pincus and Berkshire Partners for $26.00 per share in cash, after which Triumph will become a privately held company under the joint control of the two equity firms [3] - Portman Ridge Finance Corporation will be acquired by Logan Ridge Finance Corporation, with Portman Ridge remaining the surviving public entity and continuing to trade on Nasdaq under the symbol "PTMN" [4]

Core Viewpoint - Nevro (NVRO) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for predicting near-term stock price movements [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Nevro's Earnings Outlook - The recent upgrade for Nevro reflects an improvement in its underlying business, with rising earnings estimates expected to drive the stock price higher [5][10]. - Nevro is projected to earn -$2.40 per share for the fiscal year ending December 2024, showing a year-over-year change of 2.4% [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Nevro's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Company Overview - Nevro (NVRO) shares increased by 13.9% to $5.72 in the last trading session, with a notable trading volume, and have gained 43.8% over the past four weeks [1][2] Acquisition Details - Globus Medical is acquiring Nevro in an all-cash transaction valued at approximately $250 million, expected to close in late Q2 2025. This acquisition aims to leverage Nevro's innovative pain management solutions alongside Globus Medical's resources and technology [2] Financial Performance - Nevro is projected to report a quarterly loss of $0.79 per share, reflecting a year-over-year decline of 426.7%. Expected revenues are $105.65 million, down 9.1% from the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for Nevro has been revised 1.2% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [5] Industry Context - Nevro operates within the Zacks Medical - Instruments industry, where OrthoPediatrics (KIDS) recently closed 3.9% lower at $23.71, with a 2% return over the past month [5]

Group 1 - Monteverde & Associates PC is investigating Nevro Corp. in relation to its proposed merger with Globus Medical, where Globus Medical will acquire all shares of Nevro for $5.85 per share [1] - Monteverde & Associates PC has a successful track record in recovering millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report [1] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2][3] Group 2 - The firm encourages shareholders with concerns regarding Nevro Corp. to contact them for additional information free of charge [3] - Monteverde & Associates PC emphasizes that no company, director, or officer is above the law, reinforcing their commitment to shareholder rights [3] - The firm has a history of litigating and recovering money for shareholders, including cases that have reached the U.S. Supreme Court [2]

Nevro (NVRO) is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results, is expected to contribute further. However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on third-party payers persist.This Zacks Rank #2 (Buy) company’s shares have lost 49.7% in the past six months against the industry’s 3.5% growth. The S&P 500 has increased 12.1% in ...

Revenue and Financial Performance - Full-year 2024 worldwide revenues are expected to be in the range of $408 million-$409 million, representing a year-over-year decrease of approximately 4% compared to 2023 [1] - Full-year 2024 U.S. revenues are expected to be in the range of $352.5 million-$353.5 million, also reflecting a 4% decrease compared to 2023 [1] - Fourth-quarter 2024 worldwide revenues are expected to be in the range of $105 million-$106 million, representing a decrease of 9% to 10% compared to the same period in 2023 [10] - Fourth-quarter 2024 U.S. revenues are expected to be in the range of $91 million-$92 million, also reflecting a decrease of 9% to 10% compared to the same period in 2023 [10] - Cash, cash equivalents, and short-term investments are expected to be approximately $292.5 million as of Dec 31, 2024, an increase of approximately $15.5 million from Sept 30, 2024 [6] Market and Share Performance - Shares of the company have lost 27.1% in the past three months against the industry's 0.2% growth [8] - The S&P 500 has gained 0.8% during the same time frame [8] - Investors reacted negatively to the preliminary results, with the company's shares declining nearly 8% at yesterday's closing [5] Product and Clinical Developments - New data highlights long-term improvements in pain intensity for patients using High-Frequency SCS therapy, reinforcing its clinical benefits and positioning the company as a leader in pain management [3] - The publication of new data demonstrates that the SI Joint Fusion System offers significant advantages over traditional approaches, improving surgical outcomes [7] - The company received CE Mark Certification in Europe for its HFX iQ SCS system, which is likely to open up opportunities for market expansion in Europe and globally [12] Strategic Initiatives and Investments - Full-year 2024 worldwide revenues are higher than the guidance provided in November 2024, primarily due to greater-than-anticipated spinal cord stimulation (SCS) device replacement procedures in the fourth quarter [11] - The company reallocated investments to its direct-to-consumer (DTC) advertising efforts in the third quarter of 2024, with anticipated benefits ramping throughout 2025, particularly in the second half of the year [11] Industry Comparisons - Masimo (MASI) has seen its shares rise 31.7% against the industry's 1% decline in the past six months, with an average earnings surprise of 17.10% in the trailing four quarters [4] - ResMed (RMD) has an estimated earnings growth rate of 21.1% for 2025, with shares rising 31.6% against the industry's 12.8% decline in the past year [4] - Abbott (ABT) has an estimated earnings growth rate of 10% for 2025, with shares rising 8.5% in the past six months compared to the industry's 7.2% growth [9] Zacks Rankings and Estimates - The company currently carries a Zacks Rank 3 (Hold) [13] - The Zacks Consensus Estimate for full-year 2024 worldwide revenues is $403.3 million, below the preliminary figure [1] - The Zacks Consensus Estimate for fourth-quarter 2024 worldwide revenues is $100 million, below the preliminary figure [10]

Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif., Jan. 13, 2025  /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2024 revenue and other financial results. Preliminary, Unaudited Financial Highlights Fourth-quarter 2024 worldwide ...

Nevro (NVRO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a chan ...

Nevro Corp. (NVRO) recently announced the publication of new data in the journal, Medical Devices: Evidence and Research, demonstrating the superiority of the Nevro1 sacroiliac (SI) Joint Fusion System (Nevro1).Nevro1 is a posterior integrated transfixation cage system that offers enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system. Nevro1's performance also demonstrated that it is equivalent in osteopenic bone com ...